NeuroOne Expands Global Patent Portfolio with Key Approvals for Neurological Technology
NeuroOne Medical Technologies has strengthened its intellectual property position with new patent approvals in the US and Europe, signaling expanded opportunities for its neurological disorder treatment technologies.
NeuroOne Medical Technologies Corporation has significantly expanded its intellectual property portfolio with recent patent approvals from both the United States and European patent offices, positioning the company for broader technological expansion in neurological treatment markets. The medical technology company, which focuses on improving surgical care options for patients with neurological disorders, announced three key patent developments that cover critical aspects of its electrode and stimulation technologies.
The United States Patent and Trademark Office issued a Notice of Allowance for U.S. Patent Application 17/860,232, titled "Probe Devices with Temperature Sensors and Related Systems and Methods," on September 29, 2025. This patent covers novel electrode devices incorporating temperature sensors, representing an important safety feature for the company's ablation systems. A Notice of Allowance indicates the USPTO's determination that a patent should be granted following examination, with NeuroOne anticipating formal issuance in the coming months.
On October 1, 2025, the European Patent Office granted European Patent 4013481, titled "Spinal Cord Stimulation Systems, Methods, and Devices." This marks NeuroOne's first granted patent in Europe and covers innovative spinal cord stimulation devices featuring deployable electrode array technology. The patent addresses devices designed to treat lower back pain through percutaneous placement, potentially eliminating the need for surgical incisions in certain treatment scenarios.
The company received additional validation on October 7, 2025, when the USPTO issued U.S. Patent 12,435,407, titled "Methods for Making Probe Devices and Related Devices." This patent covers proprietary manufacturing methods for neural probe and spinal cord stimulation devices, including specific techniques for arranging probe components and depositing electrode contact materials. These manufacturing innovations contribute to the development of thin-film electrode technologies with optimized functionality and minimized profiles.
Dave Rosa, chief executive officer of NeuroOne, emphasized the strategic importance of these developments. "NeuroOne has made tremendous progress expanding our robust patent portfolio. Our goal is to continue to grow our technology platform to broader use cases and applications," Rosa stated. He specifically highlighted the temperature control feature as "an integral feature of our OneRF Ablation System that provides a critical safety measure for brain ablations for patients suffering from seizures."
The expanded patent portfolio now includes four additional issued U.S. patents, seven pending U.S. applications, and eight pending foreign applications covering various thin-film electrode technologies. This intellectual property foundation supports the company's development of minimally invasive solutions for conditions including epilepsy, Parkinson's disease, dystonia, essential tremors, and chronic pain resulting from failed back surgeries. For additional information about the company's technology platform, visit https://nmtc1.com.
The recent patent approvals represent significant milestones in NeuroOne's efforts to establish comprehensive protection for its neurological treatment technologies across major global markets. The European patent grant particularly signals the company's expanding international presence and potential for market entry in European healthcare systems. These developments come as the medical technology sector increasingly recognizes the importance of robust intellectual property portfolios in securing competitive advantages and attracting strategic partnerships.